StockNews.com Upgrades Emergent BioSolutions (NYSE:EBS) to Buy

Emergent BioSolutions (NYSE:EBS) was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating in a research note issued to investors on Tuesday.

Other analysts have also recently issued reports about the company. Benchmark boosted their price objective on Emergent BioSolutions from $8.00 to $12.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. HC Wainwright reissued a “buy” rating and issued a $15.00 price target on shares of Emergent BioSolutions in a report on Friday.

Emergent BioSolutions Stock Performance

Shares of NYSE:EBS traded down $0.04 on Tuesday, hitting $9.37. 1,111,748 shares of the company were exchanged, compared to its average volume of 1,008,043. The company’s 50 day moving average price is $9.36 and its two-hundred day moving average price is $9.17. The firm has a market capitalization of $507.70 million, a price-to-earnings ratio of -2.29 and a beta of 1.60. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.47 and a current ratio of 2.88. Emergent BioSolutions has a one year low of $1.42 and a one year high of $15.10.

Institutional Investors Weigh In On Emergent BioSolutions

Several institutional investors and hedge funds have recently made changes to their positions in EBS. Acadian Asset Management LLC increased its holdings in Emergent BioSolutions by 267.5% during the 2nd quarter. Acadian Asset Management LLC now owns 108,566 shares of the biopharmaceutical company’s stock valued at $739,000 after purchasing an additional 79,028 shares in the last quarter. American Century Companies Inc. increased its stake in shares of Emergent BioSolutions by 240.9% in the second quarter. American Century Companies Inc. now owns 881,893 shares of the biopharmaceutical company’s stock valued at $6,015,000 after buying an additional 623,201 shares in the last quarter. Federated Hermes Inc. raised its holdings in shares of Emergent BioSolutions by 1,314.0% in the second quarter. Federated Hermes Inc. now owns 273,287 shares of the biopharmaceutical company’s stock valued at $1,864,000 after buying an additional 253,960 shares during the last quarter. Vanguard Personalized Indexing Management LLC acquired a new position in Emergent BioSolutions during the 2nd quarter worth about $93,000. Finally, Hsbc Holdings PLC grew its holdings in Emergent BioSolutions by 36.1% during the 2nd quarter. Hsbc Holdings PLC now owns 87,679 shares of the biopharmaceutical company’s stock worth $614,000 after acquiring an additional 23,250 shares during the last quarter. Institutional investors and hedge funds own 78.40% of the company’s stock.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.